Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Lieberman

Showing results (961-970 of 1,142) with videos related to

Pageof 115
Sort By:
Molecular Psychiatry|January 10, 2018
Hippocampal dysfunction in the pathophysiology of schizophrenia: a selective review and hypothesis for early detection and interventionJ A Lieberman, R R Girgis, G Brucato, et al.
Journal of Clinical Psychopharmacology|December 17, 2014
Association study of GABAA α2 receptor subunit gene variants in antipsychotic-associated weight gainClement C H Zai, Arun K Tiwari, Nabilah I Chowdhury, et al.
Biological Psychiatry|November 28, 2019
Hippocampal Pathology in Clinical High-Risk Patients and the Onset of SchizophreniaFrank A Provenzano, Jia Guo, Melanie M Wall, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|February 5, 2020
Double blind, two dose, randomized, placebo-controlled, cross-over clinical trial of the positive allosteric modulator at the alpha7 nicotinic cholinergic receptor AVL-3288 in schizophrenia patientsJoshua T Kantrowitz, Daniel C Javitt, Robert Freedman, et al.
The American Journal of Psychiatry|June 4, 2008
Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trialDavid L Sultzer, Sonia M Davis, Pierre N Tariot, et al.
Schizophrenia Research|August 30, 2005
The Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndromeJonathan M Meyer, Henry A Nasrallah, Joseph P McEvoy, et al.
Neuron|April 16, 2013
Imaging patients with psychosis and a mouse model establishes a spreading pattern of hippocampal dysfunction and implicates glutamate as a driverScott A Schobel, Nashid H Chaudhury, Usman A Khan, et al.
Gastro Hep Advances|August 12, 2024
Colorectal Cancer Polygenic Risk Score Is Associated With Screening Colonoscopy Findings but Not Follow-Up OutcomesBrian A Sullivan, Xuejun Qin, Thomas S Redding, et al.
The International Journal of Neuropsychopharmacology|September 9, 2006
Association study of tardive dyskinesia and twelve DRD2 polymorphisms in schizophrenia patientsClement C Zai, Rudi W Hwang, Vincenzo De Luca, et al.
American Journal of Epidemiology|January 17, 2009
Association between body mass index and colorectal neoplasia at follow-up colonoscopy: a pooling studyElizabeth T Jacobs, Dennis J Ahnen, Erin L Ashbeck, et al.
Pageof 115

Showing results (961-970 of 1,142) with videos related to

Sort By:
Pageof 115
Molecular Psychiatry|January 10, 2018
Hippocampal dysfunction in the pathophysiology of schizophrenia: a selective review and hypothesis for early detection and interventionJ A Lieberman, R R Girgis, G Brucato, et al.
Journal of Clinical Psychopharmacology|December 17, 2014
Association study of GABAA α2 receptor subunit gene variants in antipsychotic-associated weight gainClement C H Zai, Arun K Tiwari, Nabilah I Chowdhury, et al.
Biological Psychiatry|November 28, 2019
Hippocampal Pathology in Clinical High-Risk Patients and the Onset of SchizophreniaFrank A Provenzano, Jia Guo, Melanie M Wall, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|February 5, 2020
Double blind, two dose, randomized, placebo-controlled, cross-over clinical trial of the positive allosteric modulator at the alpha7 nicotinic cholinergic receptor AVL-3288 in schizophrenia patientsJoshua T Kantrowitz, Daniel C Javitt, Robert Freedman, et al.
The American Journal of Psychiatry|June 4, 2008
Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trialDavid L Sultzer, Sonia M Davis, Pierre N Tariot, et al.
Schizophrenia Research|August 30, 2005
The Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndromeJonathan M Meyer, Henry A Nasrallah, Joseph P McEvoy, et al.
Neuron|April 16, 2013
Imaging patients with psychosis and a mouse model establishes a spreading pattern of hippocampal dysfunction and implicates glutamate as a driverScott A Schobel, Nashid H Chaudhury, Usman A Khan, et al.
Gastro Hep Advances|August 12, 2024
Colorectal Cancer Polygenic Risk Score Is Associated With Screening Colonoscopy Findings but Not Follow-Up OutcomesBrian A Sullivan, Xuejun Qin, Thomas S Redding, et al.
The International Journal of Neuropsychopharmacology|September 9, 2006
Association study of tardive dyskinesia and twelve DRD2 polymorphisms in schizophrenia patientsClement C Zai, Rudi W Hwang, Vincenzo De Luca, et al.
American Journal of Epidemiology|January 17, 2009
Association between body mass index and colorectal neoplasia at follow-up colonoscopy: a pooling studyElizabeth T Jacobs, Dennis J Ahnen, Erin L Ashbeck, et al.
Pageof 115